Benralizumab for treating hypereosinophilic syndrome

Benralizumab is currently in clinical development for the treatment of Hypereosinophilic Syndrome (HES). HES is a group of rare inflammatory disorders characterised by a high number of eosinophils in the blood (eosinophils are a type of white blood cell involved in the body’s immune response). When eosinophils infiltrate (enter) tissues, they can cause inflammation and organ damage which, over time, can impact patients’ day-to-day ability to function. Although any organ or organ system can be affected in HES, the most common are the heart, central nervous system, skin, and respiratory tract.